Table 1.
Basic characteristics, maternal characteristics, intervention measures, observation time, outcome indicators, and quality assessment of the included literature.
| Author | Year | Type of study | Population characteristics | Total cases | E/C cases | Experimental group intervention characteristics | Control group intervention characteristics | Observation time point | Outcome indicators | Quality assessment |
|---|---|---|---|---|---|---|---|---|---|---|
| Mathad et al. (9) | 2021 | Prospective cohort | Pregnant HIV-infected Women with sage of 14–34 weeks | 50 | 25/25 | once-weekly doses of RPT (900 mg) and INH (900 mg) for 16 weeks | Placebo during pregnancy | 34 weeks after delivery | (a) (b) (c) (d) (e) (f) | 8 |
| Mokhele et al. (10) | 2021 | Prospective cohort | women diagnosed with laboratoryconfrmed MDR/RR-TB | 35 | 17/18 | at least two second-line agents: Kanamycin/Moxifoxacin | Placebo | N/A | (a) (b) (c) (f) | 8 |
| Gupta et al. (11) | 2019 | multicenter, double-blind, placebo-controlled trial | HIV-infected pregnant women with ART | 956 | 477/479 | Begin IPT during pregnancy for 28 weeks | Placebo during pregnancy | 48 weeks after delivery | (a) (b) (c) (d) (e) (f) | A |
| Taylor et al. (12) | 2013 | multicenter, double-blind, placebo-controlled trial | HIV-infected pregnant women with ART | 196 | 103/93 | (n = 103) 6 months of isoniazid (300–400 mg/day) plus vitamin B6 (25 mg/day) + 30 months isoniazid | (n = 93) 6 months of isoniazid (300–400 mg/day) plus vitamin B6(25 mg/day) + Placebo | 30 months after delivery | (a) | B |
| Salazar-Austin et al. (13) | 2020 | Prospective cohort | pregnant women living with HIV aged ≥18 years and at least >13 weeks' gestation | 155 | 71/84 | 2 months of IPT exposure during pregnancy | NO IPT | N/A | (d) (f) | 7 |
| Yang et al. (14) | 2015 | Randomized controlled trial | Latent tuberculosis infection patients | 120 | 70/50 | Isoniazid Combined with rifampicin | Placebo | N/A | (f) | C |
| Theron et al. (15) | 2021 | multicenter, double-blind, placebo-controlled trial | pregnant women living with HIV at ≥14 through to ≤ 34 weeks and 6 days gestation | 926 | 460/466 | 28 weeks of IPT during pregnancy | Placebo during pregnancy | 48 weeks after delivery | (f) | A |
| Moro et al. (16) | 2018 | Prospective cohort | pregnant women with high-risk of latent tuberculosis infection | 125 | 87/38 | 12-dose once-weekly regimen of isoniazid (H, 900 mg) plus rifapentine (P, 900 mg) | Placebo during pregnancy | N/A | (f) | 6 |
E/C, experiment/control; MDR/RR-TB, multidrug-resistant and rifampicin-resistant tuberculosis; ART, antiretroviral therapy; IPT, isoniazid preventive therapy; RPT, rifapentine; INH, isoniazid; N/A, not available.
Outcomes: (a) any serious adverse event; (b) hepatotoxicity rate; (c) peripheral neuropathy; (d) maternal death toll; (e) permanent discontinuation of trial regimen because of toxic effects; (f) adverse pregnancy outcomes.